Browsing by author "Scolyer, Richard A"
Sort by:
Title A-Z
-
Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF) A Pilot Randomized Clinical Trial
Ackermann, Deonna M; Dieng, Mbatho; Medcalf, Ellie; Jenkins, Marisa C; van Kemenade, Cathelijne H; Janda, Monika; Turner, Robin M; Cust, Anne E; Morton, Rachael L; Irwig, Les; Guitera, Pascale; Soyer, Peter; Mar, Victoria; Hersch, Jolyn; Low, Donald; Low, Cynthia; Saw, Robyn P. M; Scolyer, Richard A; Drabarek, Dorothy; Espinoza, David; Azzi, Anthony; Lilleyman, Alister M; Smit, Amelia K; Murchie, Peter; Thompson, John F; Bell, Katy J.L.Published 2022Patient-led surveillance is a promising new model of follow-up care following excision of localized melanoma. Objective To determine whether patient-led surveillance in patients with prior localized primary cutaneous ...Open AccessArticle -
Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?
Semsarian, Caitlin R; Ma, Tara; Nickel, Brooke; Scolyer, Richard A; Ferguson, Peter M; Soyer, Peter; Parker, Lisa; Barratt, Alexandra; Thompson, John F; Bell, Katy J.L.Published 2022Many countries have seen a dramatic increase in the reported incidence of cutaneous melanoma in recent decades, largely driven by increased diagnoses of melanoma in situ and thin invasive melanoma. The incidence of thick ...Open AccessArticle -
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Luke, Jason J; Rutkowski, Piotr; Queirolo, Paola; Del Vecchio, Michele; Mackiewicz, Jacek; Chiarion-Sileni, Vanna; de la Cruz Merino, Luis; Khattak, Muhammad A; Schadendorf, Dirk; Long, Georgina V; Ascierto, Paolo A; Mandala, Mario; De Galitiis, Federica; Haydon, Andrew; Dummer, Reinhard; Grob, Jean-Jacques; Robert, Caroline; Carlino, Matteo S; Mohr, Peter; Poklepovic, Andrew; Sondak, Vernon K; Scolyer, Richard A; Kirkwood, John M; Chen, Ke; Diede, Scott J; Ahsan, Sama; Ibrahim, Nageatte; Eggermont, Alexander M M; Investigators, KEYNOTE-716Published 2022Background Pembrolizumab prolongs progression-free and overall survival among patients with advanced melanoma and recurrence-free survival in resected stage III disease. KEYNOTE-716 assessed pembrolizumab as adjuvant ...Article
Sort by:
Title A-Z